11:03 AM
 | 
Mar 22, 2019
 |  BC Week In Review  |  Clinical News  |  Clinical Status

FDA places hold on Venclexta for multiple myeloma

FDA issued a safety warning after it placed a partial clinical hold on all trials evaluating Venclexta venetoclax to treat multiple myeloma after an interim analysis showed that the drug led to a higher proportion of deaths in the Phase III BELLINI trial compared with placebo.

AbbVie Inc. (NYSE:ABBV) and Roche (SIX:ROG; OTCQX:RHHBY) market...

Read the full 247 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >